Anti-CD19 mAb modified mesoporous titanium dioxide as exclusively targeting vector for efficient B-lymphoblastic leukemia therapy
Release Time:2022-10-05 Hits:
Date of Publication: 2022-10-05
Journal: JOURNAL OF PHARMACEUTICAL SCIENCES
Institution: 党委组织部（党校）
Volume: 110
Issue: 7
Page Number: 2733-2742
ISSN: 0022-3549
Key Words: "B-lymphoblastic leukemia; CD19; DOX; Mesoporous titanium dioxide nanoparticles (MTNs)"